^
BIOMARKER:

KRAS K117

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
2ms
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation (clinicaltrials.gov)
P1, N=95, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2022 --> Feb 2024 | Trial primary completion date: Oct 2022 --> Jan 2024
Clinical • Preclinical • Trial completion date • Trial primary completion date • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS exon 2 mutation • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
irinotecan • BI 1701963
2ms
KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. (PubMed, JCO Precis Oncol)
Patients with mCRC with a KRAS A146 mutation represent a distinct molecular subgroup of patients with higher tumor burden and worse clinical outcomes, who might benefit from more intensive treatments. These results highlight the importance of testing colorectal cancer for all KRAS mutations in routine clinical care.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS Q61 • KRAS A146 • KRAS K117
|
Avastin (bevacizumab)
5ms
Clinical • Preclinical • Trial completion date • Trial primary completion date • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
|
BI 1701963 • LNP3794
9ms
Clinical • Enrollment open • Preclinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
|
BI 1701963 • LNP3794
10ms
Clinical • New P1 trial • Preclinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
|
BI 1701963 • LNP3794
1year
Clinical • Enrollment open • Preclinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS exon 2 mutation • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
irinotecan • BI 1701963
1year
Clinical • New P1 trial • Preclinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS exon 2 mutation • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
irinotecan • BI 1701963
over1year
[VIRTUAL] Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (AACR-II 2020)
The clonal and subclonal mutational landscapes of RAS WT pts were analyzed using a mCRC-focused custom ctDNA sequencing panel. Randomized pts (1:1) received mFOLFOX6 plus either panitumumab or bevacizumab. The validated ultra-deep plasma sequencing panel was concordant with tissue sequencing and detected tumor heterogeneity. The PARADIGM study will report the efficacy of anti-EGFR/VEGF therapies; post-treatment collection of ctDNA is ongoing. The relationship between therapeutic effects and clonal and subclonal mutational landscapes will be examined in the future.
P3 data
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • VEGFA (Vascular endothelial growth factor A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • KRAS G13 • KRAS G12 • NRAS G12 • NRAS G13 • NRAS Q61 • KRAS Q61 • KRAS A146 • KRAS K117 • NRAS A146 • NRAS A59 • PIK3CA mutation + PTEN mutation + KRAS mutation
|
Avastin (bevacizumab) • Vectibix (panitumumab)